LATEST
NEWS
Spotlight on faecal incontinence in the Journal of Cell and Gene Therapy Insights
The causes and impacts of faecal incontinence are being highlighted in the latest edition of the...
How AMELIE could address unmet needs in treatment of faecal incontinence
Professor Charles Knowles, Clinical Chief Investigator of AMELIE Project, discusses our research...
New regenerative approaches to treat faecal incontinence
Professor Richard Day is the Principal Investigator of the AMELIE project. He discusses how...
AMELIE survey shows faecal incontinence considered a serious public health problem
Faecal incontinence (FI) is a common condition affecting about 67 million people in Europe. Many of these people may be incontinent because of an injury – often from childbirth. AMELIE’s research into regenerative medicine and cell therapy aims to help these people. As part of the AMELIE project, we used a survey to find out what people think about FI and regenerative medicine in different European countries.
Action needed to address stark inequalities in care across UK pelvic floor services
Bowel Research UK welcomes the findings of a new report which reveals significant short-comings in the care of UK patients with pelvic floor disorders (PFDs), and provides recommendations on six areas for change to improve outcomes.
Pelvic floor services in the UK need to change
A new report, ‘Seizing the opportunity to improve patient care: Pelvic Floor services in 2021 and beyond’ exposes significant shortcomings in the care of patients with pelvic floor disorders in the UK. It provides national and local recommendations to improve healthcare services.
Can BOTOX injections help fix incontinence?
For millions of Britons it is a secret they dare not discuss. A problem they put up with, silently, often for decades. Incontinence will affect 40 per cent of women, and one in ten men at some point in their lives.
The Health Research Institute of the Jiménez Díaz Foundation participates in a clinical trial on the treatment of fecal incontinence with cell therapy
Fecal incontinence is a disease that affects some 67 million people in Europe. Although severity and presentation may be compatible with social life, it often overrides it entirely.
The latest to combat fecal incontinence: cell therapy
Fecal incontinence (FI) affects one in 20 Europeans. Although the severity and the way it presents itself are not life-threatening, this condition often ends up nullifying the social relationships of the people who suffer from it. And, its management continues to be a challenge for Medicine because a definitive optimal treatment for it has not yet been determined.
In search of a therapy against the disease that most affects social life
There are people who manage to live with it, but for most suffering fecal incontinence is synonymous with completely ending their social life, the main consequence of suffering from one of the diseases that cause the most stigma, as shown by never talking or writing about it subject.
AMELIE project: a new clinical study for CVBF
We are happy to announce that CVBF will be involved in the new project AMELIE – Anchored Muscle cELIs for IncontinencE aimed to test a new clinical approach for the treatment of faecal incontinence (FI) arising from childbirth injury in women.